Management of Multidrug Resistant Infections in Lung Transplant Recipients with Cystic Fibrosis.
Jaideep VaziraniThomas CrowhurstC Orla MorrisseyGregory I SnellPublished in: Infection and drug resistance (2021)
Cystic fibrosis (CF) is an inherited multisystem disease characterised by bronchiectasis and chronic respiratory infections which eventually cause end stage lung disease. Lung transplantation (LTx) is a well-established treatment option for patients with CF-associated lung disease, improving survival and quality of life. Navigating recurrent infections in the setting of LTx is often difficult, where immune suppression must be balanced against the constant threat of infection. Sepsis/infections are one of the major contributors to post-LTx mortality and multiresistant organisms (eg, Burkholderia cepacia complex, Mycobacterium abscessus complex, Scedosporium spp. and Lomentospora spp.) pose a significant threat to survival. This review will summarize current and novel therapies to assist with the management of multiresistant bacterial, mycobacterial, viral and fungal infections which threaten the CF LTx cohort.
Keyphrases
- cystic fibrosis
- pseudomonas aeruginosa
- multidrug resistant
- mycobacterium tuberculosis
- lung function
- sars cov
- type diabetes
- cardiovascular disease
- intensive care unit
- acute kidney injury
- cardiovascular events
- extracorporeal membrane oxygenation
- escherichia coli
- septic shock
- free survival
- coronary artery disease
- combination therapy